Skip to main content
Caplight Logo









Remagine Labs

Remagine Labs

Private
MelbourneHealthcare & Life Scienceshttps://www.remaginelabs.com/

Last Round

Pre Seed

Aug 4, 2025

Total Funding Raised

$3.16M

Company Overview

Remagine Labs is a therapeutic devices company developing a wearable, electronically controlled drug delivery system for chronic conditions like epilepsy.

Sector

Healthcare & Life Sciences

Verticals

Medical Devices, Precision Medicine, Biotechnology, Health IoT

Business Model

B2B

Customer Profile

Hardware + Subscription, Services & Consulting

AI Layer

Application

Keywords

transdermal drug deliverywearable patchdrug delivery platformiontophoresissmart patchdrug-device combinationprogrammable dosingelectro-pharmaceuticalwearable medical deviceneurological disordersprecision medicineepilepsy treatmentessential tremorbiopharma partnerships

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Remagine Labs Comparables

Compare Remagine Labs with similar companies based on industry and business-model similarity.

Remagine Labs comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
Ategenos Pharmaceuticals
83%
Biotts
72%
Nemaura Pharma
71%

Remagine Labs Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
Pre SeedAug 4, 2025
GrantMar 8, 2024

Key People

Founding team and executive leadership

Patrick Kelly

Chief Executive Officer

Executive Team

Remagine Labs Investors

Notable investors and investment history

Market signals

Structured signals derived from secondary market and firmographic data.

  • Jan 8, 2026

    Monthly visitors increased 235% to 937.

  • Dec 8, 2025

    Monthly visitors grew 48% MoM.

Recent news

Latest coverage and updates

  • is_developingJul 7, 2026

    Remagine Labs, Inc. is developing iontophoretic transdermal patch for the delivery of ulixacaltamide on Jul 7th '26.

Remagine Labs Filings

Explore SEC and related filing metadata, where available.

Remagine Labs filings preview — column headings only; records require access
TypeDateAmount OfferedAmount SoldFilingPagesDownload

Filing documents are not displayed on this public page. Request access to learn about available coverage.

Request access

Frequently Asked Questions

Common questions about Remagine Labs's valuation, stock price, and market status.

Is Remagine Labs a public or private company?

Remagine Labs is a private company.

What is the current stock price of Remagine Labs?

Remagine Labs is a private company with no public stock price. No recent secondary market data is available.

How much is Remagine Labs worth (valuation)?

Valuation information for Remagine Labs is not publicly available.

Can I buy Remagine Labs stock?

Remagine Labs shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors. Visit https://www.caplight.com to learn more.

When was Remagine Labs's last funding round?

Remagine Labs's most recent funding round was Pre Seed on August 4, 2025.

Who are the main investors in Remagine Labs?

Key investors in Remagine Labs include Monash University, Australian Government Department of Industry, Science and Resources, Breakthrough Victoria, Tin Alley Ventures.

Will Remagine Labs IPO soon?

No public IPO plans have been announced for Remagine Labs.

How can I track Remagine Labs secondary market activity?

Caplight tracks bids, offers, and trades for private companies. Visit https://www.caplight.com to monitor Remagine Labs's secondary market activity and sign up for updates.

Firmographic Details

HeadquartersMelbourne
Employee Range7
Year FoundedN/A
Last FundingAug 4, 2025

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.

See something wrong or outdated?